Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Sponsor: Novartis Pharmaceuticals
Summary
A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
Official title: A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
180
Start Date
2025-02-07
Completion Date
2033-02-26
Last Updated
2026-04-06
Healthy Volunteers
No
Conditions
Interventions
Remibrutinib (Blinded)
Remibrutinib (Blinded) active treatment
Placebo
Placebo
Remibrutinib (Open Label)
Remibrutinib (Open Label) active treatment
Locations (95)
Neuromuscular Research Center
Phoenix, Arizona, United States
Honor Health Research Institute
Scottsdale, Arizona, United States
Fullerton Neuro and Headache Ctr
Fullerton, California, United States
University Of Southern California
Los Angeles, California, United States
Univ Cali Irvine ALS Neuromuscular
Orange, California, United States
SFM Clinical Research LLC
Boca Raton, Florida, United States
Homestead Assoc In Research Inc
Homestead, Florida, United States
AdventHealth
Orlando, Florida, United States
Neurological Services of Orlando PA
Orlando, Florida, United States
Mid Atlantic Epilepsy and Sleep Ctr
Bethesda, Maryland, United States
Michigan State University-Department of Neurology
East Lansing, Michigan, United States
Dent Neurological Institute
Buffalo, New York, United States
Univ of Cincinnati Medical Center
Cincinnati, Ohio, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Houston Methodist Hospital
Houston, Texas, United States
UT Health Science Center
Houston, Texas, United States
University of WA Division of Cardio
Seattle, Washington, United States
Center for Neurological Disorders G
Greenfield, Wisconsin, United States
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
Capital Federal, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Argentina
Novartis Investigative Site
Kogarah, New South Wales, Australia
Novartis Investigative Site
Fitzroy, Victoria, Australia
Novartis Investigative Site
Southport, Australia
Novartis Investigative Site
Leuven, Vlaams Brabant, Belgium
Novartis Investigative Site
London, Ontario, Canada
Novartis Investigative Site
Ottawa, Ontario, Canada
Novartis Investigative Site
Hefei, Anhui, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Shijiazhuang, Hebei, China
Novartis Investigative Site
Wuhan, Hubei, China
Novartis Investigative Site
Wuxi, Jiangsu, China
Novartis Investigative Site
Changchun, Jilin, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Kutaisi, Georgia
Novartis Investigative Site
Tbilisi, Georgia
Novartis Investigative Site
Tbilisi, Georgia
Novartis Investigative Site
Mangalore, Karnataka, India
Novartis Investigative Site
Nashik, Maharashtra, India
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India
Novartis Investigative Site
Ludhiana, Punjab, India
Novartis Investigative Site
Vellore, Tamil Nadu, India
Novartis Investigative Site
Hyderabad, Telangana, India
Novartis Investigative Site
Lucknow, Uttar Pradesh, India
Novartis Investigative Site
Bergamo, BG, Italy
Novartis Investigative Site
Orbassano, TO, Italy
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Nishinomiya, Hyōgo, Japan
Novartis Investigative Site
Hanamaki, Iwate, Japan
Novartis Investigative Site
Sendai, Miyagi, Japan
Novartis Investigative Site
Suita, Osaka, Japan
Novartis Investigative Site
Higashi-Matsuyama, Saitama, Japan
Novartis Investigative Site
Koshigaya, Saitama, Japan
Novartis Investigative Site
Shinjuku Ku, Tokyo, Japan
Novartis Investigative Site
Chiba, Japan
Novartis Investigative Site
Fukushima, Japan
Novartis Investigative Site
Hiroshima, Japan
Novartis Investigative Site
Lublin, Lublin Voivodeship, Poland
Novartis Investigative Site
Lublin, Lublin Voivodeship, Poland
Novartis Investigative Site
Krakow, POL, Poland
Novartis Investigative Site
Bydgoszcz, Woj Kujawsko Pomorskie, Poland
Novartis Investigative Site
Bydgoszcz, Poland
Novartis Investigative Site
Katowice, Poland
Novartis Investigative Site
Lodz, Poland
Novartis Investigative Site
Lublin, Poland
Novartis Investigative Site
Lublin, Poland
Novartis Investigative Site
Poznan, Poland
Novartis Investigative Site
Skorzewo, Poland
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Brasov, Romania
Novartis Investigative Site
Bucharest, Romania
Novartis Investigative Site
Sibiu, Romania
Novartis Investigative Site
Busan, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative Site
Lleida, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Málaga, Spain
Novartis Investigative Site
Valencia, Spain
Novartis Investigative Site
Kaohsiung City, Taiwan
Novartis Investigative Site
Tainan, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Taoyuan District, Taiwan